Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+0.75%
-0.77%
ALVO
Alvotech
$9.48
Chart
$9.38 (+1.07%)
$11.55 (-17.92%)
$11.55 (-17.92%)
$12.01 (-21.07%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.75%
-0.77%
ALVO
Alvotech
Current Price
$9.48
Login to view Alvotech (ALVO) recommendation from the last 90 days from financial news and social media.
Chart
$9.38 (+1.07%)
$11.55 (-17.92%)
$11.55 (-17.92%)
$12.01 (-21.07%)
ALVO Latest Analysis
Alvotech Secures Interest Rate Reduction on Senior Secured Term Loan Facility Projected Savings of $8.2 Million. Alvotech announces interest rate reduction on its loan facility saving $8.2 million in the first year due to improved performance.
Today
Main Results of 2025 Annual and Extraordinary General Meeting. REYKJAVÍ.K Iceland and LUXEMBOURG June 25 2025 (GLOBE NEWSWIRE) -- The 2025 Annual and Extraordinary General Meeting (the 2025 AGM) of Alvotech (the Company) was held on June 25 2025 at Arendt House 41A Avenue John F. Kennedy L-2082 Luxembourg Grand Duchy of Luxembourg.
Wed Jun 25, 2025
Alvotech reports positive results in study for Xolair biosimilar.
Wed Jun 25, 2025
Alvotech Kashiv Biosciences and Advanz Pharma Announce Positive Results for AVT23 a Proposed Biosimilar to Xolair®. Alvotech Kashiv and Advanz Pharma report positive results for their biosimilar AVT23 compared to Xolair in clinical study.
Wed Jun 25, 2025
Alvotech Kashiv Biosciences and Advanz Pharma Announce Positive Results from Efficacy Study of AVT23 a Biosimilar to Xolair®. Alvotech Kashiv and Advanz announce successful efficacy study results for AVT23 a proposed biosimilar to Xolair®. for CSU treatment.
Wed Jun 25, 2025
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab). REYKJAVIK Iceland and PISCATAWAY N.J. and LONDON June 25 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide Kashiv Biosciences LLC (Kashiv) a fully integrated biopharmaceutical company headquartered in New Jersey US and Advanz Pharma Holdco Limited (Advanz Pharma) a UK-he
Wed Jun 25, 2025
Biosimilars Market Outlook Growth Trends Regulatory Landscape and Opportunities 2025–2034 | Exactitude Consultancy. Luton Bedfordshire United Kingdom June 23 2025 (GLOBE NEWSWIRE) -- Biosimilars Market Report: 2024–2025 OverviewForewordBiosimilars have emerged as a powerful tool in the global healthcare arsenal delivering cost-effective alternatives to high-priced biologics and expanding patient access. As policymakers payers providers and manufacturers align incentives around value biosimilars
Mon Jun 23, 2025
Alvotech completes private placement with 40 institutional investors.
Wed Jun 11, 2025
Alvotechs Private Placement Completed with Delivery of SDRs and Shares to Investors. Alvotech (NASDAQ: ALVO ALVO-SDB the Company) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide today announced the completion of a private placement that was carried out on June 4 2025 directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from
Wed Jun 11, 2025
Alvotechs Private Placement Completed with Delivery of SDRs and Shares to Investors. Alvotech (NASDAQ: ALVO ALVO-SDB the Company) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide today announced the completion of a private placement that was carried out on June 4 2025 directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from
Wed Jun 11, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ALVO Stock trends
ALVO Stock performance
ALVO Stock analysis
ALVO investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
